Table 2. In vivo blockade of PD-L2, but not PD-L1, results in a reduced incidence of Mf within the blood and pleural cavity.

	Incidence of blood Mf				Incidence of PC Mf
	IgG	αPD-L1	αPD-L2	αPD-L1 + αPD-L2	IgG	αPD-L1	αPD-L2	αPD-L1 + αPD-L2
Exp 1	3/6	3/3	1/6	2/5	4/6	3/3	1/6	1/5
Exp 2	3/6	5/6	1/6	2/5	3/6	4/5	4/6	3/5
Exp 3	5/8	5/7	4/7	3/7	7/8	7/7	4/7	3/7
Total	11/20	13/16	6/19*	7/17*	14/20	14/15	9/19*	7/17*
	(55%)	(81%)	(32%)	(41%)	(70%)	(93%)	(47%)	(41%)

^*Significant difference in Mf incidence driven by αPD-L2 treatment, p<0.001 (GLM using combined data from three experiments).